Monitoring the quality of life in patients with coronary artery disease

https://doi.org/10.1016/0002-9149(94)90555-XGet rights and content

Abstract

Monitoring the outcomes of treatment and quantifying patients' functional status have assumed a prominent role in both clinical trials and quality assurance programs. Because patients with coronary artery disease (CAD) may have comorbid illnesses, and because generic health status questionnaires may not focus on symptoms and impairments unique to coronary disease, a generic measure of health status may not be sufficient to detect important changes in patients' CAD. The responsiveness to clinical change of the Seattle Angina Questionnaire (SAQ), a disease-specific measure for CAD, was compared with that of the Short Form-36, a generic measure of health status. Both questionnaires were serially administered, 3 months apart, to 45 patients undergoing coronary angioplasty and to 130 patients with stable CAD. Most scales of both questionnaires improved significantly after coronary angioplasty. The responsiveness statistics of the SAQ exceeded those of the Short Form-36. Among 130 patients with initially stable angina, 33 deteriorated, 79 remained stable, and 18 improved over 3 months of observation. Mean SAQ scores changed significantly and appropriately in each of these groups. In contrast, none of the Short Form-36 scales detected these more subtle changes. Although useful in assessing overall function, a generic health status measure, such as the Short Form-36, may not be responsive enough to detect important clinical changes in patients' CAD. A disease-specific instrument, such as the SAQ, can be an important and relevant outcome measure in clinical trials or quality assurance programs.

References (20)

  • G Guyatt et al.

    Measuring change over time: assessing the usefulness of evaluative instruments

    J Chronic Dis

    (1987)
  • CL Nelson et al.

    Relation of clinical and angiographic factors to functional capacity as measured by the Duke activity status index

    Am J Cardiol

    (1991)
  • G Brown et al.

    Regression of CAD as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

    N Engl J Med

    (1990)
  • DH Blackenhorn et al.

    Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerotic Regression Study (MARS)

    Ann Intern Med

    (1993)
  • The GUSTO Investigators

    An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction

    N Engl J Med

    (1993)
  • Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2

    Lancet

    (1988)
  • WD Weaver et al.

    Pre-hospital-initiated vs hospital-initiated thrombolytic therapy: The Myocardial Infarction Triage and Intervention trial

    JAMA

    (1993)
  • GIS-SI-2: a factorial randomised trial of alteplase versus streptokinase and heparin ver-sus no heparin among 12,490 patients with acute myocardial infarction

    Lancet

    (1990)
  • E Braunwald et al.

    An approach to evaluating thrombolytic therapy in acute myocardial infarction: the unsatisfactory endpoint

    Circulation

    (1992)
  • GH Guyatt et al.

    Measuring health-related quality of life

    Ann Intern Med

    (1993)
There are more references available in the full text version of this article.

Cited by (355)

View all citing articles on Scopus

This research was supported by HSR&D Project IIR #93133R and CSHS #7 from the Department of Veterans' Affairs, Veterans' Health Administration, Health Services Research and Development Service, Seattle, Washington.

1

Dr. Spertus was a Health Services Research and Development fellow at the Seattle Veterans' Affairs Medical Center.

View full text